In the same vein, Lilly's Mounjaro is approved by the FDA for diabetes ... Adam Spatacco has positions in Eli Lilly and Novo ...

Eli Lilly's obesity drug Mounjaro will be available through Britain's state health system for some patients from March, after ...

CEO's newfound preference for Eli Lilly's (NYSE:LLY) weight loss therapy Mounjaro over Novo Nordisk's (NVO) rival product ...

Britons paying privately for obesity drugs are increasingly choosing Eli Lilly's Mounjaro over Novo Nordisk's Wegovy, online ...

In a recent head-to-head study involving Novo Nordisk 's Wegovy, Zepbound came out on top, resulting in average weight loss ...

The obesity drug race is heating up in more ways than one.Eli Lilly, the world’s biggest pharmaceutical company by market ...

Eli Lilly & Co.’s weight-loss and diabetes drug Mounjaro won’t be reclassified as a sleep apnea treatment in Europe, with regulators saying Friday that use of the drug is already covered in ...

Here's how the maker of Mounjaro and Zepbound is looking at southeast Wisconsin and the rest of the state as it continues to grow. Fast-growing drugmaker Eli Lilly and Co. would consider Wisconsin ...

Eli Lilly's key products, Mounjaro and Zepbound, dominate the U.S. weight loss market. Read more to see why I rate LLY stock ...

Stock Editorial via Getty Images An expert panel of the EU drug regulator, the European Medicines Agency (EMA), has ...

Don't Miss our Black Friday Offers: Terence Flynn’s rating is based on the performance and potential of Eli Lilly & Co’s key products, particularly Mounjaro and Zepbound. These medications ...

The U.K. will start offering Eli Lilly’s (LLY) weight loss drug Mounjaro next year, but will restrict the medicine to people with the greatest need as the country tries to adapt to new ways of ...